Cytokinetics (CYTK) Stock Forecast & Price Target

Compare

1,186 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CYTK Analyst Ratings

Strong Buy

11 Buy

2 Hold

0 Sell

Based on 13 analysts giving stock ratings to

Cytokinetics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CYTK Stock 12 Month Forecast

Average Price Target

$81.50

▲(26.04% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for Cytokinetics in the last 3 months. The average price target is $81.50 with a high forecast of $120.00 and a low forecast of $61.00. The average price target represents a 26.04% change from the last price of $64.66.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"30":"$30","121":"$121","52.75":"$52.8","75.5":"$75.5","98.25":"$98.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":120,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$120.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":81.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$81.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":61,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$61.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[30,52.75,75.5,98.25,121],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,66.05,70.2,74.35,78.5,82.65,86.8,90.95,95.1,99.25,103.4,107.55,111.7,115.85,{"y":120,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,66.05,67.23846153846154,68.42692307692307,69.61538461538461,70.80384615384615,71.99230769230769,73.18076923076923,74.36923076923077,75.5576923076923,76.74615384615385,77.93461538461538,79.12307692307692,80.31153846153846,{"y":81.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,66.05,65.66153846153846,65.27307692307691,64.88461538461539,64.49615384615385,64.1076923076923,63.71923076923077,63.33076923076923,62.94230769230769,62.55384615384615,62.16538461538462,61.776923076923076,61.38846153846154,{"y":61,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":50.63,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.04,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.46,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.5,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.92,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.21,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.64,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.69,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.62,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.84,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.59,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.05,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$120.00

Average Price Target$81.50

Lowest Price Target$61.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Ashwani Verma

UBS

$41→$61

Hold

-5.66%

Downside

Reiterated

12/02/25

Analysts Conflicted on These Healthcare Names: Cytokinetics (NASDAQ: CYTK) and CVS Health (NYSE: CVS)Cytokinetics Inc ... We raise our PT to $61 (below), but reiterate Neutral. Rating: Neutral, Price Target: US$61 (Prior: $41)

Tessa Romero

J.P. Morgan

―

Buy

―

Reiterated

11/25/25

Promising Prospects for Cytokinetics' Aficamten in oHCM and nHCM Markets

Leonid Timashev

RBC Capital

$82→$87

Buy

34.55%

Upside

Reiterated

11/10/25

RBC Capital Keeps Their Buy Rating on Cytokinetics (CYTK)

Joseph Pantginis

H.C. Wainwright

$120

Buy

85.59%

Upside

Reiterated

11/10/25

Promising Potential of Cytokinetics' Aficamten Drives Buy Rating Amid Anticipated U.S. ApprovalWe reiterate our Buy rating and $120 price target.

Mayank Mamtani

B. Riley Securities

$80→$90

Buy

39.19%

Upside

Reiterated

11/10/25

B. Riley Securities Remains a Buy on Cytokinetics (CYTK)

Srikripa Devarakonda

Truist Financial

―

Buy

―

Reiterated

11/07/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Cory Kasimov

Evercore ISI

$80

Buy

23.72%

Upside

Reiterated

11/06/25

Cytokinetics (CYTK) Gets a Buy from Evercore ISI

Serge Belanger

Needham

$72

Buy

11.35%

Upside

Reiterated

11/06/25

Analysts Offer Insights on Healthcare Companies: Contineum Therapeutics, Inc. Class A (NASDAQ: CTNM) and Cytokinetics (NASDAQ: CYTK)We maintain our Buy rating and $72PT.

Maxwell Skor

Morgan Stanley

$65

Buy

0.53%

Upside

Reiterated

11/06/25

Strategic Positioning and Launch Readiness Propel Cytokinetics to 'Buy' Rating

James Condulis

Stifel Nicolaus

$95

Buy

46.92%

Upside

Reiterated

11/06/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Bio-Techne (NASDAQ: TECH), Cytokinetics (NASDAQ: CYTK) and Jazz Pharmaceuticals (NASDAQ: JAZZ)

Jason Zemansky

Bank of America Securities

$62→$63

Hold

-2.57%

Downside

Reiterated

11/05/25

Cytokinetics' Market Uncertainty and Competitive Pressures Lead to Hold RatingWe don’t disagree aficamten looks clinically competitive, but absent insights as to whether this is enough to drive upside, especially given Bristol’s/ Camzyos’ advantages and market dynamics keeps us at Neutral.

Carter Gould

Cantor Fitzgerald

―

Buy

―

Reiterated

10/21/25

Cytokinetics (CYTK) Gets a Buy from Cantor Fitzgerald

Gena Wang

Barclays

$71→$82

Buy

26.82%

Upside

Reiterated

10/06/25

Analysts Are Bullish on These Healthcare Stocks: Cytokinetics (CYTK), Sanofi (SNYNF)Reiterate OW and increase our PT to $82.

David Lebowitz

Citi

$77→$84

Buy

29.91%

Upside

Reiterated

09/03/25

Cytokinetics' Aficamten Poised to Transform Hypertrophic Cardiomyopathy Treatment Landscape Following Promising Phase 3 Results

Akash Tewari

Jefferies

$80

Buy

23.72%

Upside

Reiterated

09/03/25

Cytokinetics (CYTK) Gets a Buy from Jefferies

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Ashwani Verma

UBS

$41→$61

Hold

-5.66%

Downside

Reiterated

12/02/25

Tessa Romero

J.P. Morgan

―

Buy

―

Reiterated

11/25/25

Promising Prospects for Cytokinetics' Aficamten in oHCM and nHCM Markets

Leonid Timashev

RBC Capital

$82→$87

Buy

34.55%

Upside

Reiterated

11/10/25

RBC Capital Keeps Their Buy Rating on Cytokinetics (CYTK)

Joseph Pantginis

H.C. Wainwright

$120

Buy

85.59%

Upside

Reiterated

11/10/25

Promising Potential of Cytokinetics' Aficamten Drives Buy Rating Amid Anticipated U.S. ApprovalWe reiterate our Buy rating and $120 price target.

Mayank Mamtani

B. Riley Securities

$80→$90

Buy

39.19%

Upside

Reiterated

11/10/25

B. Riley Securities Remains a Buy on Cytokinetics (CYTK)

Srikripa Devarakonda

Truist Financial

―

Buy

―

Reiterated

11/07/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Cory Kasimov

Evercore ISI

$80

Buy

23.72%

Upside

Reiterated

11/06/25

Cytokinetics (CYTK) Gets a Buy from Evercore ISI

Serge Belanger

Needham

$72

Buy

11.35%

Upside

Reiterated

11/06/25

Analysts Offer Insights on Healthcare Companies: Contineum Therapeutics, Inc. Class A (NASDAQ: CTNM) and Cytokinetics (NASDAQ: CYTK)We maintain our Buy rating and $72PT.

Maxwell Skor

Morgan Stanley

$65

Buy

0.53%

Upside

Reiterated

11/06/25

Strategic Positioning and Launch Readiness Propel Cytokinetics to 'Buy' Rating

James Condulis

Stifel Nicolaus

$95

Buy

46.92%

Upside

Reiterated

11/06/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Bio-Techne (NASDAQ: TECH), Cytokinetics (NASDAQ: CYTK) and Jazz Pharmaceuticals (NASDAQ: JAZZ)

Jason Zemansky

Bank of America Securities

$62→$63

Hold

-2.57%

Downside

Reiterated

11/05/25

Carter Gould

Cantor Fitzgerald

―

Buy

―

Reiterated

10/21/25

Cytokinetics (CYTK) Gets a Buy from Cantor Fitzgerald

Gena Wang

Barclays

$71→$82

Buy

26.82%

Upside

Reiterated

10/06/25

Analysts Are Bullish on These Healthcare Stocks: Cytokinetics (CYTK), Sanofi (SNYNF)Reiterate OW and increase our PT to $82.

David Lebowitz

Citi

$77→$84

Buy

29.91%

Upside

Reiterated

09/03/25

Cytokinetics' Aficamten Poised to Transform Hypertrophic Cardiomyopathy Treatment Landscape Following Promising Phase 3 Results

Akash Tewari

Jefferies

$80

Buy

23.72%

Upside

Reiterated

09/03/25

Cytokinetics (CYTK) Gets a Buy from Jefferies

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Cytokinetics

1 Month

xxx

Success Rate

14/19 ratings generated profit

Average Return

+16.42%

reiterated a xxx

rating 10 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 73.68% of your transactions generating a profit, with an average return of +16.42% per trade.

3 Months

xxx

Success Rate

11/19 ratings generated profit

Average Return

+28.95%

reiterated a xxx

rating 10 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 57.89% of your transactions generating a profit, with an average return of +28.95% per trade.

1 Year

Joseph PantginisH.C. Wainwright

Success Rate

13/17 ratings generated profit

Average Return

+25.86%

reiterated a buy rating 25 days ago

Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 76.47% of your transactions generating a profit, with an average return of +25.86% per trade.

2 Years

xxx

Success Rate

16/17 ratings generated profit

Average Return

+37.34%

reiterated a xxx

rating 25 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 94.12% of your transactions generating a profit, with an average return of +37.34% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CYTK Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CYTK has received 14 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. CYTK average Analyst price target in the past 3 months is 81.50.

Each month's total comprises the sum of three months' worth of ratings.

CYTK Financial Forecast

CYTK Earnings Forecast

Next quarter’s earnings estimate for CYTK is -$1.41 with a range of -$2.14 to -$0.20. The previous quarter’s EPS was -$2.55. CYTK beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year CYTK has Performed in-line its overall industry.

CYTK Sales Forecast

Next quarter’s sales forecast for CYTK is $10.03M with a range of $0.00 to $50.00M. The previous quarter’s sales results were $1.94M. CYTK beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year CYTK has Performed in-line its overall industry.

CYTK Stock Forecast FAQ

What is CYTK’s average 12-month price target, according to analysts?

Based on analyst ratings, Cytokinetics’s 12-month average price target is 81.50.

What is CYTK’s upside potential, based on the analysts’ average price target?

Cytokinetics has 26.04% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CYTK a Buy, Sell or Hold?

Cytokinetics has a consensus rating of Strong Buy which is based on 11 buy ratings, 2 hold ratings and 0 sell ratings.

What is Cytokinetics’s price target?

The average price target for Cytokinetics is 81.50. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $120.00 ,the lowest forecast is $61.00. The average price target represents 26.04% Increase from the current price of $64.66.

What do analysts say about Cytokinetics?

Cytokinetics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of CYTK?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Cytokinetics (CYTK) Stock Forecast & Price Target

CYTK Analyst Ratings

CYTK Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Cytokinetics

CYTK Analyst Recommendation Trends

CYTK Financial Forecast

CYTK Earnings Forecast

CYTK Sales Forecast

CYTK Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts